R
ather than an exhaustive review, this article will attempt concise consideration of some key controversies in critical care nutrition. Excellent, mostly evidence-based guidelines for feeding intensive care unit (ICU) patients have recently been published (1) . Here we will focus on hyperglycemia, immunonutrition, and route of feeding. Treatment of hyperglycemia in the ICU has major implications for the use of nutritional support and is a topic that is currently the focus of a variety of clinical trials. Immunonutrition refers specifically to the use, usually in enteral feeds, of specific substances purported to have immunomodulatory actions independent of the mere provision of diet. Clear advantages have been shown in surgical patients in comparison with standard enteral formulae; however, immunonutrition in the ICU has been variously reported to both increase and decrease mortality. Finally, we will examine the questionable adage that enteral nutrition is superior to parenteral nutrition and discuss how aggressive use of early enteral feeding might improve outcome for patients.
Hyperglycemia
Before 2001, interest in glucose control in the ICU appeared to be rather low. Nonrandomized studies of effects of insulin therapy on infectious complications of cardiothoracic surgery suggested the benefit of tighter glucose control (2) . Few standardized policies existed, perhaps because stress-related insulin resistance leading to mild hyperglycemia was considered an adaptive phenomenon (3) and might even have benefits for the systemic inflammatory response by providing greater amounts of glucose for anaerobic metabolism to key cells such as macrophages and fibroblasts. Observational data suggested that serum glucose values Ͼ200 mg/dL were associated with increases in infectious complications in surgical inpatients, so a frequent response was initiation of subcutaneous insulin therapy only for glucose values consistently in excess of this threshold (4) . Abrupt changes in ICU policy were implemented in response to the publication of a large, randomized trial that showed a mortality benefit from the use of intensive insulin therapy in a mainly surgical critical care unit in Belgium (5) . The controls were not given insulin unless hyperglycemia (glucose value, Ͼ215 mg/dL) was demonstrated. The experimental group was treated to true normoglycemia (80 -110 mg/dL), with initiation of insulin infusions when glucose values rose to Ͼ110 mg/dL.
A major strength of this study is its large size (1,548 patients) and complete follow-up; however, several points need to be considered before widespread implementation of this protocol. Absence of blinding, which admittedly would have been extraordinarily difficult, allows the possibility that more attention was paid to the experimental group, particularly with regard to the need for observation for hypoglycemia. Serious hypoglycemia, even though not associated with obvious clinical sequelae, was substantially more frequent in the intensive insulin group, and herein lies a question of broad applicability. Smaller community hospitals might not have sufficient personnel to implement these intensive insulin strategies but may do so anyway, resulting in higher rates of hypoglycemia. A subsequent analysis of the original trial revealed that a majority of the hypoglycemic events occurred during unplanned interruption of enteral feeding (6) .
Assuming that normoglycemia can be safely applied in the ICU, one must determine which patients are likely to benefit. In the Van den Berghe study, 70% of enrollees were cardiothoracic surgical patients, and only 20% had medical conditions. Thus, it may perhaps be premature to implement intensive insulin therapy in a medical ICU without further data, which should be shortly forthcoming from several randomized trials. What is notable about the Belgian trial is that no mortal-ity benefit was realized among patients who were discharged from the ICU within 5 days of admission. All the advantages of the therapy were for longer-stay patients, and the major benefit appeared to be in prevention of multiple-organ failure with a septic focus. It is interesting that two thirds of this subgroup had not undergone cardiothoracic surgery, a circumstance suggesting broader applicability of the therapy. Numerous other positive outcomes were listed, such as a lower incidence of renal failure and of polyneuropathy, although these are likely associated sequelae of septic multiple-organ failure and thus perhaps would be expected to be lowered by any strategy that prevents the latter.
From the perspective of a nutritional support practitioner, perhaps the most ignored facet of this study was that all of the patients in both groups were treated with relatively high-dose intravenous dextrose from ICU admission and were maintained on nutritional support for the duration of the ICU admission. The initial level of feeding approximated 8 kcal/kg on average and approached 24 kcal/kg by day 5 of feeding, with an eventual goal of 20 -30 nonprotein kcal/kg/24 hrs with 0.13-0.26 g nitrogen/kg preferably by enteral feeding, which represents a nearly optimal energy and protein intake. This may be a major difference to many other ICU practices, in which most nutritional support is initiated by the enteral route, leading to much lower amounts of dextrose provided initially and lower energy and protein subsequently than were given in the Belgian study. Notably, patients fed exclusively total parenteral nutrition (TPN) who remained in the ICU for Ͼ5 days required 26% higher insulin doses than those fed at least partially by the enteral route.
Further analysis revealed that it was the metabolic control related to normoglycemia rather than insulin dose that determined the beneficial effects (6) . Hyperglycemia induces a state of oxidative stress and cytokine activation (7, 8) , which insulin can directly suppress (9, 10) . The antiinflammatory effect of insulin therapy on acute-phase protein production was found both in the Belgian study (11) and in a study of burn patients (12) . Although in the latter study it was thought that insulin had a direct effect beyond the establishment of better glucose control, the two groups were matched for glucose control, with only one group receiving insulin (12) , which makes the two groups not truly comparable for this variable.
An observational study in England characterized by intense monitoring of blood glucose was unable to confirm that true normoglycemia should be the standard of care (13) . All patients reviewed were treated with intensive insulin therapy in an attempt to maintain glucose values between 90 and 145 mg/dL. Regression analyses that included all glucose values recorded on all participants suggested a benefit to maintenance of glucose somewhere below a threshold in the 145-180 mg/dL range. However, this is seriously confounded by the effect of insulin resistance (which is clearly correlated with illness severity) to impair the ability to reach lower blood sugars for a given dose of insulin (14) . Other reasons why one might anticipate a different recommended goal for plasma glucose value from this study include uncertain amounts of nutrition received in the English study, as well as a much shorter length of stay. A large observational study of the effects of implementation of an insulin program with a goal of maintenance of blood glucose levels Ͻ140 mg/dL showed that mortality and length of stay for the first 800 patients treated with the protocol were significantly lower than for the 800 patients admitted to the ICU immediately before starting the protocol (15) . In this case, use of any supplemental nutritional support was not mentioned. Other differences from the Belgian study were that most of the patients were medical ICU patients, that insulin infusions were started only for glucose values Ͼ200 mg/dL, and that no changes were seen in infectious complications.
In the coronary care unit, benefit was seen in the use of intensive insulin to lower 1-yr mortality for all patients presenting with myocardial infarction (MI) who had evidence of hyperglycemia, irrespective of a prior diagnosis of diabetes (16, 17) . However, nutritional support was not considered for these patients, and it was deemed possible that part of the benefit of insulin was as a component of glucose-insulin-potassium (GIK) therapy, originally described by Sodi-Pallares (18) . A second large randomized trial of intense metabolic control (Diabetes Insulin-Glucose in Acute Myocardial Infarction, or DIGAMI 2) did not show a difference in outcome in terms of morbidity or mortality, but glycemic control did not differ in the intensive insulin control group (19) . However, glucose level was an important predictor of long-term mortality in this study, supporting the hypothesis (19) . A recent meta-analysis of GIK therapy suggested the benefit of this modality in the treatment of acute MI, in terms of mortality (20) . More recently, GIK therapy for acute MI has not been shown to be of any benefit in a very large randomized trial of 20,201 patients (21). However, there are both metabolic and cardiologic concerns with this study. The glucose control in the treatment group was significantly poorer and in the higher risk area by the criteria of both the Belgian and English studies described above. The cardiologic concerns were related to the timing of the therapy and the very high mortality associated with the reperfusion therapy (22) . Thus, one must revisit the idea of tight glucose control for cardiac patients in the light of the Belgian study. Nonetheless, most straightforward critical care unit patients admitted with acute MI do not receive nutritional support and thus need to be studied separately from the typical malnourished ICU patients.
Clearly, this is such an important topic that many other trials of tight and less stringent glycemic control are under way, with the goal being to define a threshold for glucose values above which the complications of hyperglycemia are evident. Until that time, for surgical patients receiving 200 -300 g/day of dextrose, an attempt to maintain values as close to normoglycemia as can safely be done within the limits of the institution is prudent. To achieve this end, approximately 0.3 U/hr/kcal/kg of insulin were needed on average over the first 2 days in the Belgian trial. On subsequent days, even though nutritional intake was increasing, hourly doses of insulin were gradually reduced, with ongoing maintenance of normoglycemia.
Immunonutrition
Since nutritional support began, various dietary components have been used in an attempt to modulate immune function. To this end, specific amino acids, long chain fatty acids, and nucleic acids have been studied in amounts in excess of what is required for nutrition replacement, and this topic has been called "immunonutrition" (23) .
The most popular enteral formulae that have been studied in this context are Impact and Immun-Aid, although several others exist. The important clinical similarities and what distinguishes these formulae from traditional enteral feeds is the inclusion of substantial amounts of arginine, n-3 fatty acids, and nucleotides (Table 1 ). It is not clear which constituents are most responsible for the immune-enhancing aspect of the solution, as the components have generally not been rigorously and independently tested in large trials.
Arginine is considered to be a "conditionally essential" amino acid, in that endogenous synthesis may be limited during illness, and thus it is a major component of most commercial immunonutrition formulae. Supplementation with arginine in trials of postoperative patients results in beneficial effects on T cells (24) and wound healing (25, 26) . Use of immunonutrition solutions with arginine concentrations ‫6ف‬g/L ‫%2ف(‬ energy) have generally led to negative results (27, 28) , whereas solutions with arginine concentrations Ͼ12 g/L (Ͼ4% energy) were often positive. There are no studies showing that addition of nucleotides to the diet of humans might be beneficial, although nucleotides are plentiful in breast milk and are perhaps immunomodulatory in infants. Animal studies have shown a variety of effects on the immune system, but these have not been replicated in human experiments.
The reason for inclusion of n-3 polyunsaturated fatty acids (PUFA) is more readily apparent. Such fatty acids are the precursors of eicosanoids, including prostaglandins, prostacyclins, thromboxanes, and leukotrienes. Linoleic acid [18: 2n-6] (the 'essential fatty acid' that ultimately gives rise to arachidonic acid [20: 4n-6] ) is potentially proinflammatory by its leading to increasing production of interleukin 1, tumor necrosis factor ␣, and interleukin 6, which increase eicosanoid production (29) . Addition of n-3 PUFA as eicosapentaenoic acid (EPA) [20: 5n-3] limits this proinflammatory effect:
EPA inhibits both ⌬6 and ⌬5 desaturase, the former being rate-limiting in the conversion of linoleic acid to arachidonic acid. In addition, EPA replaces arachidonic acid in cell membrane phospholipids, which is associated with production of prostaglandins and leukotrienes (3 and 5 series, respectively) with reduced proinflammatory potential. Docosahexaenoic acid (DHA) [20:6n-3 ] is anti-inflammatory in its own right through the production of compounds called resolvins and docosatrienes (30) . Other potential mechanisms of n-3 PUFA need to be considered, however. The n-3 PUFA are natural ligands for certain nuclear receptors and may lead to changes in gene expression that might impact clinical outcome. In addition, their insertion into cell membranes can alter membrane fluidity, which affects multiple aspects of cell signaling.
Therefore, n-3 fatty acids, which are included in the main commercial formulae that are available for immunonutrition and are readily transferred from the diet into cell membranes, are antiinflammatory (31) . It is important to distinguish the source of n-3 fatty acids, however. The anti-inflammatory properties have been particularly related physiologically to the EPA and DHA. The amount of n-3 fatty acids as EPA and DHA needed for effectiveness in immuneenhancing diets is about 1g/day (32). Alpha-linolenic acid [18:3n-3] , the other essential fatty acid, is converted by desaturation and elongation to EPA and then on to DHA, but this conversion rate is slow and inefficient, with only about 8% of dietary fatty acid being so converted (33, 34) . Thus fats containing relatively large amounts of alpha-linolenic acid, such as canola, soy, and linseed oil, lead to lesser amounts of EPA and DHA in tissue membranes than smaller quantities of fish oil containing EPA and DHA (35) . Some of the atypical results found in studies of immune-enhancing diets may be due to the variable sources of n-3 fatty acids contained in the formulas.
Just as in the previous discussion that a beneficial outcome in critically ill patients might require the presence of two elements, both adequate feeding and tight blood glucose control, such may be the case with immunonutrition, where a critical level of both arginine and n-3 fatty acids needs to be present to see benefit. For example, a study of a diet enriched only in arginine (3.2%), fed successfully by the nasogastric route in adequate amounts to medical patients with Acute Physiology and Chronic Health Evaluation (APACHE) scores between 13 and 21, had no impact on infection rates, length of stay, or mortality (36) . The systemic inflammatory response generally has both proinflammatory and anti-inflammatory components, and adverse outcomes may come from excessive degrees of either (37) . Thus, in a heterogeneous critically ill population, n-3 fatty acids may be beneficial in those with excessive proinflammatory responses, whereas arginine alone without n-3 fatty acids might even be harmful. In other patients, where excessive anti-inflammation and immune suppression are predominant, an immunostimulant like arginine might be beneficial to promote immune function and wound healing. In patients with a balance of proinflammatory and antiinflammatory components, the combination of the two might be synergistic if the enhancement of the systemic inflammatory response by arginine could increase immune competence without exacerbating inflammation.
Few controversies exist with regard to the finding that in gastrointestinal surgery, in which most patients have a substantial degree of malnutrition, infectious complications can be reduced by use of immunonutrition vs. standard enteral formulae. Where most of the uncertainty lies is in the critically ill popula- tion. A number of trials have been conducted in ICUs, with diverse results. In trauma patients, studies involving randomization between an immune-enhancing formula and appropriate isonitrogenous control have limited sample sizes for the most part. Unfortunately, the only large study used an inappropriately low protein control formula (38) , and thus did not address the question of whether an immune-enhancing formula is superior to isonitrogenous "regular" feeding. The data are not overwhelmingly in favor of immunonutrition for trauma patients, although they do suggest a benefit. The only two well-controlled trials, by Mendez (28) and Kudsk (39) et al., showed radically different outcomes, one positive and the other without effect upon infectious complications. The major differences were that the negative trial appeared to have more patients with acute respiratory distress syndrome (ARDS) in the treatment group, used an experimental formula that contained substantially less arginine (6.6 vs. 14 g/L), included alpha-linolenic acid as the source of n-3 fatty acids, and did not contain nucleotides, raising the consideration that the exact constituents of the feed may be of paramount importance. In general ICU populations, heterogeneity of patients is likely to be greater than in gastrointestinal cancer or trauma; thus, varied results should not be surprising. Four large studies of ICU patients (40 -43) have been published, although one (42) used an inappropriate control solution that provided less protein. In this particular study, there were more deaths in the immunonutrition group (not significant) and no benefits to immunonutrition by intention-to-treat analysis. Immunonutrition reduced mortality in a second study (44) , whereas the two largest (41, 43) showed no difference vs. control by intention to treat.
Of research interest, on subgroup analysis the Bower study (42) showed improved outcome in subgroup analysis of those with adequate intake of the diet (Ͼ820 mL/day). Similarly, in the Atkinson study (41) , in an a priori identified group with adequate intake (Ͼ833 mL/ day), and overall in the Galban study (40) , where Ͼ84% of subjects received Ͼ820 mL/day, immunonutrition did provide benefit. This would suggest that adequate intake of the immune-enhancing formula might be important, but in the Kieft study, which showed no difference, virtually all patients received Ͼ820 mL/day (43) . However, the one major difference in these studies was that the same immune-enhancing formula containing Ͼ4%(4.8%) arginine was used in the Bower, Atkinson, and Galban studies, whereas substantially less (2.9%) was used in the immune-enhancing formula in the Kieft study (43) . All four studies received greater than 1 g n-3 fatty acid as EPA and DHA. Given that the two nutrients most likely to improve outcome in immune-enhancing diets are arginine at Ͼ4% energy and n-3 fatty acids as EPA or DHA of at least 1 g/day (32), it would appear that the Kieft study did not fully test the hypothesis. However, given the size of the Kieft study, it is difficult at this time to recommend immunonutrition in the ICU population ( Table 2) .
A subgroup of ICU patients, those with burns, has been examined in three studies of immunonutrition, one of which one was composed mostly of trauma patients and was too small for subgroup analyses (45) . Of the two others (46, 47) , only one had controls randomized to an appropriate control formula, and this did not show benefits over usual enteral feeding (47) .
Attempts at resolution of the controversy through meta-analysis have not been definitive, with somewhat different conclusions from four different data sets and with the overall suggestion that this therapy can lower rates of infection but not overall mortality (48 -51) . Subsequent to these meta-analyses, interim results from a subgroup of ICU patients with severe sepsis were reported (52) . The participants were enrolled in a larger study of a comparison of TPN versus early enteral immunonutrition (using a formula that was relatively low in arginine-6.8 g/L [2.8%]-and contained alpha-linolenic acid as the source of n-3 fatty acids). The study was terminated early for the subgroup of septic patients because of a substantial increase in ICU mortality in the immunonutrition group. Overwhelming sepsis portends a grim prognosis, which is unlikely to be altered substantially by substituting one form of nutrition for another. The usual current recommendation has emerged that immunonutrition be avoided in those patients who are very seriously ill, with APACHE scores Ͼ20, especially those with sepsis (1, 23) . Attempting to modulate the immune system in such a patient population likely requires use of stronger ammunition, such as drugs or antibodies that block cytokine production or action (53) 
ence, immune-enhancing nutrition in particular) is most likely to improve outcome.
The effect of gender has been noted only in the most recent study (43) , which showed no benefit of immunonutrition over standard care. Women had no benefit from the therapy, whereas men did, although the authors acknowledge these conclusions are limited by their post hoc nature and need further exploration in a randomized trial.
The Importance of Route of Feeding in ICU Patients
Traditional ICU doctrine is that enteral is always better than parenteral nutrition. Early studies of TPN showed high rates of infection, usually related to hyperglycemia (54) . The very ease with which TPN can be administered allows delivery of large quantities of dextrose, with consequent hyperglycemia in critically ill, insulin-resistant patients unless insulin therapy is carefully added. Thus, many of the studies in which enteral and parenteral nutrition have been compared were seriously flawed in that unequal amounts ("overfeeding" in the case of TPN) of nutrients were delivered, and different rates of hyperglycemia surely contributed to the differences in infectious complications.
Earlier meta-analyses failed to show any benefit of TPN over enteral feeding, and thus TPN has fallen into some disrepute. This fact, combined with the animal data showing that enteral nutrition is associated with lower rates of bacterial translocation, has led to many ICU nutrition guidelines stressing the use of enteral nutrition wherever possible in preference to parenteral. However, a more recent meta-analysis of studies comparing TPN vs. enteral nutrition, which excluded poor-quality studies with pseudorandomization and high dropout rates, showed a significant mortality benefit for TPN over enteral, with little evidence of heterogeneity between studies (55). This analysis included nine randomized trials that provided intention-to-treat results. It still showed a higher rate of infectious complications in those treated with TPN, however.
Clearly, in this current era where the deleterious effects of even small eleva-tions in plasma glucose concentrations have been established, the ability to attain normoglycemia might allow some of the other benefits of TPN to be appreciated. In nutritionally depleted patients, it may be easier to get to goal feeding rates with TPN than with enteral nutrition, allowing an advantage. It is interesting that all of the mortality advantages of TPN were found in comparison with "late" enteral feeding. There was no advantage at all to TPN in comparison with early enteral feeding, in this and in a separate meta-analysis on this specific topic (56) . These findings might suggest, at least for patients at high nutritional risk, that the ability to feed early in the illness is key and that any way it can be done is fine.
Delaying feeding is associated with poorer outcomes. Meta-analyses of early vs. delayed enteral nutrition have generally concurred and showed better results in terms of infectious complications and length of hospital stay from early feeding but no effects on noninfectious complications or mortality. The most recent and comprehensive meta-analysis of ICU patients included 15 prospective randomized trials, with 753 patients overall (57). However, there are no trials at all that focus on medical ICU patients.
Evidence-based protocols have been designed with a focus on early enteral nutrition. One particularly comprehensive ICU nutrition guideline was developed by a Canadian group (1). The protocol recommended initiation of enteral nutrition within 24 hrs of ICU admission, or else using TPN. To facilitate more widespread use of enteral nutrition, aggressive use of head-upright position, postpyloric feeding tubes, and prokinetic agents was recommended in the protocol.
In addition, more rapid increases in feeding rates were proposed than are often used. A cluster randomized controlled trial was then undertaken to test the protocol, involving 14 hospitals containing mixed medical-surgical ICUs and enrolling 499 patients (58) . The intervention hospitals had a reduction in length of stay and higher numbers of days of enteral nutrition and of any nutrition. A strong trend toward a lower mortality rate was found in the hospitals randomized to use the protocol.
Similarly, in the Stanford University Veterans System, implementation of an ICU feeding protocol doubled the numbers of patients receiving enteral nutrition after adjusting for age, gender, illness severity, and underlying diagnosis. This was associated with a shorter duration of mechanical ventilation (59) . Calgary Foothills Hospital initiated a nutrition protocol for ventilated patients (60) . This led to a large increase (from 20% to 60%) of patients receiving at least 80% of their energy needs during their ICU stay and a reduction in use of TPN. Hard outcome data were not evaluated in this study. However, these careful studies all demonstrate that apathy toward feeding the ICU population early after admission is not justified and that nutritional protocols may be very advantageous (61) .
Furthermore, under randomized trial conditions, a number of recent studies have shown that nasogastric feeding can be accomplished in most critically ill patients (36, 62) . Woodcock et al. demonstrated in a largely unselected clinical population that tolerance to enteral feeding could be predicted in nearly 90% of patients (63) . For some of the remaining patients, nasojejunal feeding would be successful (64, 65) , with TPN exclusively, as an initiation regimen, or in combination therapy in certain circumstances.
In conclusion, therefore, good-quality evidence shows clearly that close attention to glucose control while feeding the ICU patient is of paramount importance, although we await more data as to appropriate glucose threshold values in different populations. Similarly, early enteral feeding-and probably parenteral feeding too, if it can be done without effecting hyperglycemia-is likely of benefit in ICU patients. Aggressive approaches toward feeding are warranted on the basis of recent studies. Exactly what the content of the nutritional support should be has not been satisfactorily resolved, and perhaps many ICU patients are too ill to benefit from immunonutrition as a means of disease manipulation. 
